Évaluation de la pratique chirurgicale dans le traitement du cancer bronchique en France à partir de la base nationale du PMSI

Bernard, Alain; Pagès, Pierre-Benoît; Mariet, Anne‐Sophie; Pforr, Arnaud; Cottenet, Jonathan; Quantin, Catherine

doi:10.1016/j.rmr.2018.01.014

Cited by 4 publications

(2 citation statements)

References 24 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The practice of lung cancer surgery in France has been the subject of several publications using the national hospital (PMSI) medico-administrative database (1)(2)(3). Although the number of hospitals performing this surgery was reduced following the implementation of the French National Cancer Plan (4), the number still remains high.…”

Section: Introductionmentioning

confidence: 99%

Is there variation between hospitals within each region in postoperative mortality for lung cancer surgery in France? A nationwide study from 2013 to 2020

et al. 2023

View full text Add to dashboard Cite

IntroductionThe practice of thoracic surgery for lung cancer is subject to authorization in France. We evaluated the performance of hospitals using 30-day post-operative mortality as a quality indicator, estimating its distribution within each region and measuring its variability between regions.Material and methodsAll data for patients who underwent pulmonary resection for lung cancer in France (2013–2020) were collected from the national hospital administrative database. Thirty-day mortality was defined as any patient who died in hospital (including transferred patients) within the first 30 days after the operation and those who died later during the initial hospitalization. The Standardized Mortality ratio (SMR) was the smoothed, adjusted, hospital-specific mortality rate divided by the expected mortality. To describe the variation in hospital mortality between hospitals in each region, we used different commonly used indicators of variation such as coefficients of variation (CV), interquartile interval or range (IQR), extreme ratio, and systematic component of variance (SCV).ResultsIn 2013–2020, 87,232 patients underwent lung resection for cancer in France. The number of deaths was 2,537, a rate of 2.91%. The median SMR of 199 hospitals was 0.99 with an IQR of 0.86 to 1.18 and a CV of 0.25. Among the regions that had the most hospitals performing lung resections for cancer, the extreme ratio was >2, which means that the maximum value is twice as high as the minimum value. The SCV between hospitals was >10 for two of these regions, which is considered indicative of very high variation. For the other regions (with few hospitals performing lung resections for cancer), the variation between hospitals was lower. Globally, the variability between regions concerning the SMR was moderate, 6% of the variance was due to differences across regions. On the contrary, the hospital volume was significantly related to the SMR (p = 0.003) with a negative linear trend, whatever the region.ConclusionThis work shows significant differences in the practices of the various hospitals within regions. However, overall, the variability in the 30-day mortality rate between regions was moderate. Our findings raises questions regarding the regionalization of major surgical procedures in France.

show abstract

Section: Introductionmentioning

confidence: 99%

Is there variation between hospitals within each region in postoperative mortality for lung cancer surgery in France? A nationwide study from 2013 to 2020

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Therefore, prevention and treatment of lung cancer is important. Currently, surgery, chemotherapy, and radiotherapy are the main treatment options for lung cancer; however, all of these options have disadvantages: surgery is risky and restrictive [4,5], chemotherapy is not completely effective and can lead to drug resistance [6], and radiotherapy is associated with serious side effects [7]. The five-year survival rates of patients with stage IA, IB, IIA, IIB, IIIA, IIIB, and IV lung cancers are 73%, 58%, 46%, 36%, 24%, 9%, and 2%, respectively [8].…”

Section: Introductionmentioning

confidence: 99%

TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment

Guo

Bai

Shi

et al. 2021

IJMS

View full text Add to dashboard Cite

Lung cancer has the highest rate of incidence and mortality among all cancers. Most chemotherapeutic drugs used to treat lung cancer cause serious side effects and are susceptible to drug resistance. Therefore, exploring novel therapeutic targets for lung cancer is important. In this study, we evaluated the potential of TMEM16A as a drug target for lung cancer. Homoharringtonine (HHT) was identified as a novel natural product inhibitor of TMEM16A. Patch-clamp experiments showed that HHT inhibited TMEM16A activity in a concentration-dependent manner. HHT significantly inhibited the proliferation and migration of lung cancer cells with high TMEM16A expression but did not affect the growth of normal lung cells in the absence of TMEM16A expression. In vivo experiments showed that HHT inhibited the growth of lung tumors in mice and did not reduce their body weight. Finally, the molecular mechanism through which HHT inhibits lung cancer was explored by western blotting. The findings showed that HHT has the potential to regulate TMEM16A activity both in vitro and in vivo and could be a new lead compound for the development of anti-lung-cancer drugs.

show abstract

Comparaison de la mortalité des résections pulmonaires en France aux autres pays Européens

Bernard¹,

Riviere²,

Cottenet³

et al. 2022

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

Évaluation de la pratique chirurgicale dans le traitement du cancer bronchique en France à partir de la base nationale du PMSI

Cited by 4 publications

References 24 publications

Is there variation between hospitals within each region in postoperative mortality for lung cancer surgery in France? A nationwide study from 2013 to 2020

Is there variation between hospitals within each region in postoperative mortality for lung cancer surgery in France? A nationwide study from 2013 to 2020

TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment

Comparaison de la mortalité des résections pulmonaires en France aux autres pays Européens

Contact Info

Product

Resources

About